Price Alert

Tvardi Therapeutics Inc. (TVRD)

NASDAQ: TVRD · Real-Time Price · USD

24.30

0.51 (2.14%)

At close: Aug 15, 2025, 3:59 PM

24.00

-1.23%

After-hours: Aug 15, 2025, 04:10 PM EDT

Tvardi Therapeutics Statistics

Share Statistics

Tvardi Therapeutics has 9.36M shares outstanding. The number of shares has increased by null% in one year.

Shares Outstanding	9.36M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Institutions (%)	n/a
Shares Floating	n/a
Failed to Deliver (FTD) Shares	5,831
FTD / Avg. Volume	9.82%

Short Selling Information

The latest short interest is 519.62K, so 0% of the outstanding shares have been sold short.

Short Interest	519.62K
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	13.49

Valuation Ratios

The PE ratio is -0.11 and the forward PE ratio is -7.74. Tvardi Therapeutics's PEG ratio is 0.

PE Ratio	-0.11
Forward PE	-7.74
PS Ratio	1.04
Forward PS	105.6
PB Ratio	-1.62
P/FCF Ratio	-0.12
PEG Ratio	0

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Tvardi Therapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 11.03, with a Debt / Equity ratio of -9.68.

Current Ratio	11.03
Quick Ratio	10.81
Debt / Equity	-9.68
Debt / EBITDA	-0.71
Debt / FCF	-0.72
Interest Coverage	-6.58

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$419.82K
Profits Per Employee	$-4.17M
Employee Count	17
Asset Turnover	0.16
Inventory Turnover	0.9

Taxes

Income Tax	-398K
Effective Tax Rate	0.56%

Stock Price Statistics

The stock price has increased by null% in the last 52 weeks. The beta is 0.21, so Tvardi Therapeutics's price volatility has been higher than the market average.

Beta	0.21
52-Week Price Change	n/a
50-Day Moving Average	25.44
200-Day Moving Average	n/a
Relative Strength Index (RSI)	45.68
Average Volume (20 Days)	59,382

Income Statement

In the last 12 months, Tvardi Therapeutics had revenue of 7.14M and earned -70.87M in profits. Earnings per share was -46.59.

Revenue	7.14M
Gross Profit	6.33M
Operating Income	-55.78M
Net Income	-70.87M
EBITDA	-62.6M
EBIT	-62.79M
Earnings Per Share (EPS)	-46.59

Full Income Statement

Balance Sheet

The company has 37.9M in cash and 44.45M in debt, giving a net cash position of -6.54M.

Cash & Cash Equivalents	37.9M
Total Debt	44.45M
Net Cash	-6.54M
Retained Earnings	-755.61M
Total Assets	38.95M
Working Capital	37.75M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -60.92M and capital expenditures -1.05M, giving a free cash flow of -61.96M.

Operating Cash Flow	-60.92M
Capital Expenditures	-1.05M
Free Cash Flow	-61.96M
FCF Per Share	-40.74

Full Cash Flow Statement

Margins

Gross margin is 88.62%, with operating and profit margins of -781.57% and -992.95%.

Gross Margin	88.62%
Operating Margin	-781.57%
Pretax Margin	-998.53%
Profit Margin	-992.95%
EBITDA Margin	-877.12%
EBIT Margin	-781.57%
FCF Margin	-868.19%

Dividends & Yields

TVRD does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for TVRD is $62, which is 161.5% higher than the current price. The consensus rating is "Buy".

Price Target	$62
Price Target Difference	161.5%
Analyst Consensus	Buy
Analyst Count	5

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	-26.18
Piotroski F-Score	5